Matrix Metalloproteinase-9 inhibitors as therapeutic drugs for traumatic brain injury
Neurochemistry International · 2024-01 · 172 · 105642
DOI: 10.1016/j.neuint.2023.105642 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurochemistry International, 2024-01. Verfasst von Angel Sunny und 6 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, Elmhurst, NY, USA. Hauptthemen laut MEDLINE: Brain Edema, Brain Injuries, Traumatic, Matrix Metalloproteinase Inhibitors. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: National Institute of Neurological Disorders and Stroke, National Institutes of Health.
Abstract (Originalsprache)
Traumatic brain injury (TBI) is one of the leading causes of morbidity and mortality among young adults and the elderly. In the United States, TBI is responsible for around 30 percent of all injuries brought on by injuries in general. Vasogenic cerebral edema due to blood-brain barrier (BBB) dysfunction and the associated elevation of intracranial pressure (ICP) are some of the major causes of secondary injuries following traumatic brain injury. Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for being an enzyme that degrades the proteins that make up a part of the microvascular basal lamina as well as inter-endothelial tight junctions of the blood-brain barrier. MMP-9-mediated BBB dysfunctions and the compromise of the BBB is a major pathway that leads the development of vasogenic cerebral edema, elevation of ICP, poor cerebral perfusion and brain herniation following traumatic brain injury. That makes MMP-9 an effective therapeutic target and endogenous or exogenous MMP-9 inhibitors as therapeutic drugs for preventing secondary brain damage after traumatic brain injury. Although our understanding of the mechanisms that underlie the primary and secondary stages of damage following a TBI has significantly improved in recent years, such information has not yet resulted in the successful development of novel pharmacological treatment options for traumatic brain injury. Recent pre-clinical and/or clinical studies have demonstrated that there are several compounds with specific or non-specific MMP-9 inhibitory properties either directly binding and inhibiting MMP-9 or by indirectly inhibiting MMP-9, with potential as therapeutic agents for traumatic brain injury. This article reviews the efficacy of several such medications and potential agents that include endogenous and exogeneous compounds that are at various levels of research and development. MMP-9-based therapeutic drug development has enormous potential in the pharmacological treatment of cerebral edema and/or neuronal injury resulting from traumatic brain injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, Elmhurst, NY, USA.
- Government Medical College, Kozhikode, India.
- Smt. Kashibai Navale Medical College, Pune, India.
- JSS Medical College, Mysore, India.
- Pushpagiri Institute of Medical Sciences and Research Centre, Thiruvalla, India.
- Department of Surgery, Morehouse School of Medicine, Atlanta, GA, USA. Electronic address: btharakan@msm.edu.
Förderung
- National Institute of Neurological Disorders and Stroke
- National Institutes of Health
Zitieren
APA
Sunny, A., James, R. R., Menon, S. R., Rayaroth, S., Daniel, A., Thompson, N. A., & Tharakan, B. (2024). Matrix Metalloproteinase-9 inhibitors as therapeutic drugs for traumatic brain injury. Neurochemistry International, 172, 105642. https://doi.org/10.1016/j.neuint.2023.105642
Vancouver
Sunny A, James RR, Menon SR, Rayaroth S, Daniel A, Thompson NA, et al. Matrix Metalloproteinase-9 inhibitors as therapeutic drugs for traumatic brain injury. Neurochemistry International. 2024;172:105642. doi:10.1016/j.neuint.2023.105642
BibTeX
@article{Sunny2024,
author = {Sunny, Angel and James, Raisa Rani and Menon, Swathi Radhakrishnan and Rayaroth, Swetha and Daniel, Abhijith and Thompson, Namita Ann and Tharakan, Binu},
title = {Matrix Metalloproteinase-9 inhibitors as therapeutic drugs for traumatic brain injury},
journal = {Neurochemistry International},
year = {2024},
volume = {172},
pages = {105642},
doi = {10.1016/j.neuint.2023.105642}
}
EUVIMED